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A systematic review was conducted to determine whether initial screening characteristics of women with normogo-
nadotrophic anovulatory infertility predict clinically signi®cant outcomes of ovulation induction with gonadotro-
phins, and to obtain pooled estimates of their predictive value through meta-analysis. Only those studies in which
pre-treatment screening characteristics (such as body mass index, serum LH and androgens, insulin sensitivity and
ultrasound appearance of ovaries) were related to outcome parameters (such as total amount of FSH administered,
cancellation, ovulation, pregnancy and miscarriage), were included in this analysis. Thirteen studies ful®lled the
inclusion criteria. A positive association was seen in all studies between the level of obesity (de®nition applied as
assessed by individual studies) and total amount of FSH administered [weighted mean difference (WMD) of 771 IU
(95% con®dence interval (CI): 700±842)]. Pooled odds ratios (OR) of 1.86 (95% CI: 1.13±3.06) and 0.44 (95% CI:
0.31±0.61) were found between obesity with cancellation and ovulation respectively. Pooled analysis did not show a
signi®cant association between obesity and pregnancy rate. The pooled OR for obese versus non-obese women and
miscarriage rate was signi®cant [3.05 (95% CI: 1.45±6.44)]. Association measures between insulin resistance (de®n-
ition applied as assessed by individual studies) and total amount of FSH administered produced a WMD of 351
(95% CI: 73±630) IU. A pooled OR of 0.29 (95% CI: 0.10±0.80) was found for insulin resistance with pregnancy
rate. The pooled OR for insulin resistance (hyperinsuliaemia versus normoinsuliaemia) and miscarriage rate was
not signi®cant. A pooled OR of 1.04 (95% CI: 1.01±1.07) was found for LH (IU/l) with pregnancy rate. The pooled
OR for LH and miscarriage rate was not signi®cant. Finally, pooled analysis did not ®nd a signi®cant association
between testosterone and pregnancy rate. In conclusion, the best available evidence, though limited, suggests that
the most clinically useful predictors of gonadotrophin ovulation induction outcome in normogonadotrophic women
are obesity and insulin resistance.
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Introduction
Chronic anovulation presents with amenorrhoea or oligomenor-
hoea and can be classi®ed on the basis of serum FSH and estradiol
(E2) levels. Hypogonadotrophic anovulation, low levels of
gonadotrophins and negligible estrogen activity, is also referred
to as (World Health Organization (WHO) group 1. Hypergonado-
trophic anovulation is characterized by elevated gonadotrophin
levels and low E2 (WHO group 3) (Lunenfeld and Insler, 1974;
ESHRE Capri Workshop Group, 1995; Rowe et al., 2000).
Normogonadotrophic anovulation (FSH and E2 levels within the
normal range) (WHO group 2) represents the most common form
of ovarian dysfunction and is a frequent cause of infertility (Laven
et al., 2002; Rowe et al., 2000).
Clomiphene citrate has been used worldwide as the medication
of ®rst choice for the treatment of these women, because it is safe,
convenient, cheap, and reasonably effective. The risk of develop-
ing ovarian hyperstimulation syndrome (OHSS) and multiple
gestation is limited (2±3%) (Imani et al., 1999). However, a
signi®cant proportion (23%) of women remain anovulatory
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following clomiphene citrate (Imani et al., 1998). A cumulative
pregnancy rate of 73% is reported in ovulatory clomiphene citrate-
treated women (Imani et al., 1999).
Induction of ovulation using exogenous gonadotrophins is
generally indicated in patients with normogonadotrophic anovu-
latory infertility who have failed to ovulate or to conceive during
previous clomiphene citrate treatment (Schwartz and Jewelewicz,
1981; Lunenfeld et al., 1985; Insler, 1988; Kelly and Jewelewicz,
1990; Franks and Gilling-Smith, 1994; Fauser and Van Heusden,
1997). Since the early 1960s, many anovulatory patients have been
treated with hMG and hCG to induce ovulation. This treatment
modality has been proven to be effective, but the risks of OHSS
(Stephenson, 1991; Navot et al., 1992) and multiple pregnancies
are considerably increased (Schenker et al., 1981; Fauser and Van
Heusden, 1997).
Recent studies have focused on the prediction of ovulation
induction outcome based upon initial screening characteristics of
WHO 2 anovulatory infertile women (Imani et al., 1998, 1999,
2002a; Mulders et al., 2003). It could be demonstrated that some
clinical, sonographic and endocrine characteristics are predictive
of ovulation and conception during clomiphene citrate treatment
(Imani et al., 1998, 1999, 2000, 2002a). Outcome parameters of
gonadotrophin treatment in these women correlated with woman's
age, ovarian response to preceding clomiphene citrate medication,
body mass index (BMI), the mean follicle number assessed by
ultrasound, serum levels of FSH, testosterone, androstenedione,
and initial insulin-like-growth factor-I (IGF-I) (Imani et al.,
2002b; Mulders et al., 2003).
The aim of gonadotrophin ovulation induction in anovulatory
infertility is healthy live-birth, preferably from a singleton
pregnancy. This is often hard to achieve despite the recent
introduction of low-dose incremental or decremental regimens
(Fauser and Van Heusden, 1997). An individualized treatment
regimen, based on valid outcome predictors, might optimize
ovulation induction strategies by improving the balance between
success and complications. The existing literature concerning the
prediction of outcome is limited and ambiguous. Some studies
observe signi®cant associations, whereas others fail to do so.
Therefore, a systematic review was undertaken to establish more
®rmly which screening parameters are predictive of outcome of
gonadotrophin induction of ovulation.
Materials and methods
The objectives of this review were to determine whether screening
criteria applied to women with normogonadotrophic anovulatory
infertility, predict clinically signi®cant outcomes of ovulation
induction with gonadotrophins, and to obtain pooled estimates of
their predictive value through meta-analysis.
Criteria for considering studies for this review
Studies reporting gonadotrophin ovulation induction in women with
normogonadotrophic anovulatory infertility [WHO 2, including
polycystic ovary syndrome (PCOS)] were considered for inclusion if
they provided speci®c information on: the regimens and type of
gonadotrophin administered, e.g. standard protocol, step-up protocol,
step-down protocol, hMG, urinary-derived (u)FSH and recombinant
(r)FSH. The following primary outcome measures were sought:
monofollicular growth [arbitrarily de®ned as one follicle >15 mm on
the day of hCG (van Santbrink and Fauser, 1997)], total amount of
gonadotrophins administered on the day of hCG in international units
(IU), cancellation rate (cycle where there is no hCG administered),
ovulation rate (as con®rmed by an increased serum progesterone level
(>20 nmol/l) in the luteal phase), pregnancy rate (per cycle or per
patient) (de®ned as a positive urinary pregnancy test) and miscarriage
rate (sonographic assessment of absence of an intrauterine gestational
sac with heart beat at 12 weeks amenorrhoea). The following
screening characteristics were also sought: age (years), cycle history
(oligo- or amenorrhoea), BMI (kg/m2), response during previous
clomiphene citrate treatment [clomiphene resistant anovulation
(CRA)/clomiphene citrate failure (CCF)], ovarian volume (ml), total
number of follicles (both ovaries) (Pache et al., 1992), ovarian stroma
echogenicity (Dewailly et al., 1994), serum levels of testosterone,
androstenedione, LH, LH/FSH, fasting insulin and glucose. Inclusion
was limited to studies in which outcome parameters were related to
pre-treatment screening characteristics.
Search strategy for the identi®cation of studies
Studies reporting the prediction of outcomes following gonadotrophin
induction were initially identi®ed through a handsearch (no speci®c
criteria: papers at hand were considered). The wide variety of key
words used in these reports provided the foundation for the ®nal search
strategy. It consisted of: (i) a Medline search by means of MESH
headings (in the following order): (follicle stimulating hormone [majr]
OR menotrophins [majr]) AND `female genital diseases and
pregnancy complications' [Majr] and (ii) a check of the bibliographies
of identi®ed studies.
Identi®cation
Through the MESH headings search strategy ((follicle stimulating
hormone [majr] OR menotrophins [majr]) AND `female genital
diseases and pregnancy complications' [Majr]), 631 titles were
identi®ed (1986 to October 2002). For 474 titles it was clear that
population or intervention did not ful®l the selection criteria. To verify
whether it was appropriate to exclude such articles based solely on
titles, one of us (A.M.) read 10 of the 474 articles. None ful®lled the
inclusion justifying this identi®cation strategy. The remaining 157
articles were then read by one author (A.M.). Twenty-three studies
ful®lled the selection criteria. All of their bibliographies were
checked. This identi®ed one additional study for inclusion.
Twenty-four potentially relevant studies were read by all authors
and 13 were included. There were no disagreements between authors
regarding the inclusion of studies.
Methods of the review
The following information was extracted from the potentially relevant
studies: study characteristics, speci®ed as observational, cohort, cross-
over, consecutive or randomized, multicentre or not, method of
randomization, number of patients/cycles (randomized, excluded and
analysed), duration, timing and location of the study. Patient
characteristics were recorded: de®nition of normogonadotrophic
anovulatory infertility (WHO 2 including PCOS) (clinical, biochem-
ical, ultrasonographic markers or combination of the former),
de®nition and duration of infertility, age, investigative work-up,
other causes of infertility and previously administered treatment(s), in
particular whether previous treatment with clomiphene citrate had
been tried and how CRA or CCF was de®ned. Finally, the outcome
measures and their speci®c de®nitions were also recorded: total
amount of exogenous FSH administered (IU), duration of adminis-
tration of exogenous FSH (days), the number of cancelled cycles, the
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number of cycles with multi- or monofollicular growth, the number of
ovulatory cycles, the number of patients pregnant and not pregnant,
miscarriage rate, multiple pregnancy rate and OHSS rate. A study had
to give either a direct measure of association between predictor and
outcome variables or present data that allowed for the calculation of
such a measure. Studies reporting relationships between initial
screening characteristics and outcome parameters of ovulation
induction as measures of association (odds ratios: OR) and studies
from which measures of association could be derived from the data
given were included. For example, if a study reported the mean and
SD of an outcome variable (eg. cancellation rate) for obese and for
lean women separately, the OR of cancellation rate for obesity could
be calculated assuming a normal distribution of the outcome variable
in both groups, by the formula: ln(OR) = (meanobese ± meanlean)/
(pooled variance in obese and lean).
Results
Studies excluded
Eleven potentially relevant studies were excluded (Table I).
These included application of modi®ed stimulation schemes
[Norfolk (1, 3, 5) regimen or administration of 150 IU every
other day] (Ginsburg and Hardiman, 1991; Remorgida et al.,
1991), application of modi®ed controlled ovarian hyperstimu-
lation followed by intrauterine and/or intraperitoneal insemin-
ation for PCOS and normo-ovulatory patients (Zullo et al.,
1996), and comparison of two different stimulation regimens
for a different subset of patients (repetitive cycles, not equally
distributed) (Shoham et al., 1991).
Six studies stated insuf®cient data to allow analysis: only P-
levels were noted for signi®cant and non-signi®cant prediction
of duration of treatment by screening parameters (Coelingh
Bennink et al., 1998), insuf®cient data were provided to
calculate OR (respectively age versus conception) (Ginsburg
and Hardiman, 1991), no clear statement of the background of
LH levels supplied (Hamilton-Fairley et al., 1991), only data of
LH pre-treatment versus ovulation for a subset of patients
(Polson et al., 1987), no original data of LH levels (separately
for pregnant and non-pregnant women) (Strowitzki et al.,
1994). Finally, data for different subsets of patients (WHO 1
and 2) were not provided separately (Fluker et al., 1994).
In one study (Abdel et al., 1990), Pearson's correlation
statistics showed a signi®cant positive correlation between the
BMI and the dose of gonadotrophins (r = 0.4666; P < 0.001).
This dose correlated negatively with ovarian volume (r =
±0.1958; P = 0.01). Since these correlation coef®cients could
not be incorporated in the pooled analysis, these data were not
included.
One study (Imani et al., 2002b) provided signi®cant
correlations between the amount of exogenous FSH required
for ovarian response [sonographic visualisation of a follicle
>10 mm (Pache et al., 1990)] and initial clinical, sonographic
and endocrine screening characteristics. Four of these param-
eters (i.e. ovarian response to clomiphene citrate medication
(CRA), BMI, initial serum levels of FSH and free IGF-I) were
included in the multivariate model to predict the FSH response
dose (i.e. the amount of exogenous FSH required for ovarian
response). Since this study only reported one speci®c outcome
parameter that was not considered in the review, this study was
excluded from the pooled analysis.
Methodological quality of included studies
A total of 13 studies was included in the current review
(Table II) (Sagle et al., 1991; Hamilton-Fairley et al., 1992;
McClure et al., 1992, 1993; Dale et al., 1993; Farhi et al., 1993;
Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997;
Dale et al., 1998; Strowitzki et al., 1998; Yarali et al., 1999;
Vicino et al., 2000). Some researchers performed several
studies concerning outcome of ovulation induction in the same
patient group of interest (Sagle et al., 1991; Hamilton-Fairley
et al., 1992; McClure et al., 1992, 1993; Dale et al., 1993,
1998; White et al., 1996). However, these studies appeared to
include a different subset of patients (Hamilton-Fairley et al.,
1992; Dale et al., 1993, 1998; White et al., 1996) or the focus
(screening characteristic versus outcome parameter) of the
studies was different (Sagle et al., 1991; Hamilton-Fairley
et al., 1992; McClure et al., 1992, 1993; White et al., 1996).
Description of participants
The de®nitions of normogonadotrophic anovulatory infertility
(WHO 2) and PCOS varied between centres, as detailed in
Table II. Patients suffering from WHO 2 anovulatory infertility
were included (Farhi et al., 1993; Balasch et al., 1996; Yarali
et al., 1999). The most comprehensive de®nition of PCOS
speci®ed as a combination of clinical features (oligoamenor-
rhoea), biochemical parameters (increased androgen concen-
trations) and polycystic appearance of ovaries on ultrasound
scan (enlarged ovaries with multiple small follicles), was used
in a number of studies (McClure et al., 1992; Fulghesu et al.,
1997; Vicino et al., 2000). Various combinations of clinical,
biochemical and ultrasonic ®ndings were also used: ultrasound
and clinical or biochemical (Sagle et al., 1991; Hamilton-
Fairley et al., 1992; Dale et al., 1993, 1998; Strowitzki et al.,
1998), clinical and ultrasound and/or biochemical (McClure
et al., 1993), or clinical and ultrasound (White et al., 1996).
According to these de®nitions, oligoamenorrhoea is not present
in all patients per se (McClure et al., 1992; Dale et al., 1993,
1998; Farhi et al., 1993; Balasch et al., 1996; Strowitzki et al.,
1998).
The extent of the infertility work-up was stated in all studies
(Sagle et al., 1991; Hamilton-Fairley et al., 1992; McClure
et al., 1992, 1993; Dale et al., 1993, 1998; Farhi et al., 1993;
Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997;
Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000).
This consisted most commonly of a semen analysis and a
hysterosalpingography and/or laparoscopic inspection. Twelve
studies included only couples with a normal semen analysis
(Sagle et al., 1991; Hamilton-Fairley et al., 1992; McClure
et al., 1992, 1993; Dale et al., 1993, 1998; Farhi et al., 1993;
Balasch et al., 1996; Fulghesu et al., 1997; Strowitzki et al.,
1998; Yarali et al., 1999; Vicino et al., 2000). In all studies,
tubal patency (at least one open tube) was con®rmed (Sagle
et al., 1991; Hamilton-Fairley et al., 1992; McClure et al.,
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1992, 1993; Farhi et al., 1993; Balasch et al., 1996; White et al.,
1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Vicino
et al., 2000). In one study, donor sperm (one patient) were used
because of co-existing male factor infertility (Hamilton-Fairley
et al., 1992).
Except for one study (White et al., 1996), the patients of
interest either had remained anovulatory after clomiphene
citrate treatment, or had failed to conceive despite ovulating
during clomiphene citrate treatment. A wide variation in the
de®nition of clomiphene citrate-resistant anovulation and
failure was used. In two studies, ovarian wedge resection or
ovarian electrocauterization had been performed before
gonadotrophin induction of ovulation (Dale et al., 1993, 1998).
In three studies, patients with increased BMI levels were
excluded from treatment: BMI >28 kg/m2 (Hamilton-Fairley
et al., 1992; White et al., 1996) and BMI >30 kg/m2 (Sagle
et al., 1991).
Description of interventions
The step-up regimen was applied according to the following
protocol: a starting dose of 75 IU per day and a ®rst dose
increase of 75 IU per day after 5±7 days (Farhi et al., 1993).
Various alternatives of this protocol were reported (McClure
et al., 1992, 1993; Fulghesu et al., 1997; Vicino et al., 2000).
Others used the step-up regimen according to the following
protocol: starting dose of 50±75 IU per day, a ®rst dose
increase of 37.5 IU per day after 14 days and a subsequent dose
increase of 37.5 IU per day (Sagle et al., 1991; Hamilton-
Fairley et al., 1992; Dale et al., 1993, 1998; Balasch et al.,
1996; White et al., 1996; Yarali et al., 1999). Strowitzky et al.
utilized a variation of this regimen. In some studies the starting
dose was adjusted in the subsequent (>1) cycle performed
(McClure et al., 1992; Balasch et al., 1996; White et al., 1996;
Yarali et al., 1999; Vicino et al., 2000).
The following preparations of gonadotrophins were used:
hMG (Sagle et al., 1991; Hamilton-Fairley et al., 1992;
McClure et al., 1992; Farhi et al., 1993; White et al., 1996),
uFSH (Sagle et al., 1991; Hamilton-Fairley et al., 1992;
McClure et al., 1992; Dale et al., 1993, 1998; Farhi et al., 1993;
Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997;
Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000)
and rFSH (Strowitzki et al., 1998; Yarali et al., 1999). Only
one study compared gonadotrophin-only treatment (uFSH/
hMG) with a combined regimen (hMG and the concomitant
administration of a GnRH agonist) (Farhi et al., 1993). Besides
gonadotrophin induction of ovulation, electrocautery was also
performed in one study (Vicino et al., 2000).
Description of outcome measures
In six studies the number of cycles with monofolllicular
development was not reported (McClure et al., 1992, 1993;
Farhi et al., 1993; White et al., 1996; Fulghesu et al., 1997;
Vicino et al., 2000). The de®nition of monofollicular growth
varied from one follicle >15 mm (Dale et al., 1998) and one
follicle >17 mm (Balasch et al., 1996) in diameter on the day of













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale et al.,
1993; Strowitzki et al., 1998; Yarali et al., 1999). Only seven
studies reported the number of cycles with monofollicular
growth (Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale
et al., 1993, 1998; Balasch et al., 1996; Strowitzki et al., 1998;
Yarali et al., 1999).
The total amount of gonadotrophins administered per cycle
(Sagle et al., 1991; McClure et al., 1992, 1993; Dale et al.,
1993; Farhi et al., 1993; White et al., 1996; Strowitzki et al.,
1998; Yarali et al., 1999; Vicino et al., 2000) or the mean total
quantity of gonadotrophins to induce ovulation or achieve
follicular maturation (Hamilton-Fairley et al., 1992; Balasch
et al., 1996; Fulghesu et al., 1997; Dale et al., 1998) was
provided for all studies in ampoules or IU. For one study
(McClure et al., 1992) the total amount of gonodotrophins
administered was deduced from a ®gure illustration. A
conversion to IU was made for those studies reporting the
total dose in ampoules (Sagle et al., 1991; Hamilton-Fairley
et al., 1992; Farhi et al., 1993; White et al., 1996; Strowitzki
et al., 1998; Vicino et al., 2000).
Criteria for cycle cancellation were based on the number of
follicles developed and/or serum E2 levels. In ®ve studies,
cycles were cancelled in case of multifollicular growth (>4
follicles >15 mm) (Sagle et al., 1991; Hamilton-Fairley et al.,
1992; Dale et al., 1993, 1998; White et al., 1996; Yarali et al.,
1999). In four studies, cycles were cancelled because of
multifollicular growth or absence of response (Balasch et al.,
1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al.,
2000). Finally, three studies cancelled treatment cycles based
on multifollicular growth and/or increased serum E2 levels
(McClure et al., 1992, 1993; Farhi et al., 1993). One study did
not provide information on criteria for cycle cancellation
(Fulghesu et al., 1997). Only nine studies reported the number
of cancelled cycles (Sagle et al., 1991; McClure et al., 1992;
Dale et al., 1993, 1998; Balasch et al., 1996; White et al., 1996;
Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000).
Criteria for ovulation were based on the assessment of serum
progesterone levels (Hamilton-Fairley et al., 1992; Dale et al.,
1993; White et al., 1996; Dale et al., 1998; Yarali et al., 1999),
or ultrasound (Strowitzki et al., 1998) or both (Sagle et al.,
1991; Fulghesu et al., 1997; Vicino et al., 2000). Four studies
did not provide information concerning con®rmation of
ovulation (McClure et al., 1992, 1993; Farhi et al., 1993;
Balasch et al., 1996). A total of 11 studies reported the number
of ovulatory cycles (Sagle et al., 1991; Hamilton-Fairley et al.,
1992; McClure et al., 1992; Dale et al., 1993; Farhi et al., 1993;
Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997;
Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000).
Explicit details of the de®nition of pregnancy were given by
using serum hCG (Sagle et al., 1991; Strowitzki et al., 1998;
Yarali et al., 1999), ultrasound (Balasch et al., 1996; Vicino
et al., 2000), serum hCG and ultrasound (Hamilton-Fairley
et al., 1992, 1993) or ultrasound and/or histological veri®cation
(Dale et al., 1993, 1998). Two studies speci®cally stated the
presence of a clinical pregnancy (Sagle et al., 1991; Yarali
et al., 1999). Finally, one study only provided data on the
de®nition of a clinical pregnancy (i.e. intrauterine gestational
sac and fetal heart beat) (Vicino et al., 2000). In four studies the
de®nition of pregnancy was not stated (McClure et al., 1992;
Farhi et al., 1993; White et al., 1996; Fulghesu et al., 1997).
Pregnancy rate (per cycle and per patient) was provided for all
studies except one (McClure et al., 1993).
The de®nition of miscarriage, spontaneous abortion or
ongoing pregnancy rate was not clearly stated in seven studies
(Farhi et al., 1993; Balasch et al., 1996; White et al., 1996;
Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al.,
1999; Vicino et al., 2000). In two studies the de®nition of early
pregnancy loss was stated (Sagle et al., 1991; Hamilton-Fairley
et al., 1992). In four studies the de®nition of miscarriage was
based on the division in ®rst and second trimester abortions
(McClure et al., 1992, 1993; Dale et al., 1993, 1998). Data on
miscarriage rates were stated in all studies except one (Vicino
et al., 2000).
Description of screening characteristics related to treatment
outcome
Except for one (Sagle et al., 1991), all studies stated data of age
(means 6 SD) for patients. In only four studies were exact data
of cycle history (i.e. oligomenorrhoea or amenorrhoea) for all
patients mentioned (Sagle et al., 1991; Hamilton-Fairley et al.,
1992; Farhi et al., 1993; Balasch et al., 1996).
Details of BMI levels for patients were given in nine studies
(Dale et al., 1993, 1998; Farhi et al., 1993; McClure et al.,
1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al.,
1997; Yarali et al., 1999; Vicino et al., 2000). Some studies
divided patients into non-obese (lean) and obese [BMI >25 kg/
m2 (Hamilton-Fairley et al., 1992; Dale et al., 1993, 1998;
White et al., 1996; Fulghesu et al., 1997), BMI >27 (Vicino
et al., 2000), or probably BMI >30 (Yarali et al., 1999)]. One
study (Strowitzki et al., 1998) described patients as lean or
obese without any further information. The fraction of obese
(BMI >25) and non-obese patients was calculated where only
continuous data of BMI were provided (McClure et al., 1992;
Farhi et al., 1993; White et al., 1996), assuming a normal
distribution.
In nine studies, CRA was de®ned as anovulation during >3
consecutive cycles with an increasing dose up to >150 mg/day
for a period of 5 days (Sagle et al., 1991; Hamilton-Fairley
et al., 1992; Dale et al., 1993, 1998; Farhi et al., 1993; Balasch
et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino
et al., 2000). One study decreased the threshold for CRA to 100
mg/day (Fulghesu et al., 1997). In one study the dose for CRA
was not clearly stated (McClure et al., 1992). CCF was de®ned
as failure to conceive after >6 ovulatory clomiphene citrate
cycles (McClure et al., 1992; Farhi et al., 1993; Fulghesu et al.,
1997; Strowitzki et al., 1998; Yarali et al., 1999). One study
decreased the number of cycles for CCF to 3 (Balasch et al.,
1996). In two other studies the number of ovulatory cycles to
ful®l the criteria for CCF were not stated (Dale et al., 1993,
1998). In two studies (McClure et al., 1993; Strowitzki et al.,
1998), patients were said to be (un)responsive or resistant to
clomiphene citrate, but the dose as well as the duration of
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clomiphene citrate treatment were not stated. In only six
studies were the exact number of patients suffering from CRA
and CCF mentioned (Sagle et al., 1991; Hamilton-Fairley et al.,
1992; McClure et al., 1992, 1993; Dale et al., 1993; Vicino
et al., 2000).
The de®nition of polycystic ovaries was based on the Adams
criteria (i.e. increased number of follicles and either an
increased ovarian volume or increased stromal area or both)
(Sagle et al., 1991; Hamilton-Fairley et al., 1992; Farhi et al.,
1993; White et al., 1996; Dale et al., 1998; Strowitzki et al.,
1998; Vicino et al., 2000), or based on the presence of an
increased number of follicles and/or ovarian stroma (McClure
et al., 1992, 1993). Others did not report (clear) information on
the de®nition of polycystic ovaries (Dale et al., 1993; Balasch
et al., 1996; Fulghesu et al., 1997; Yarali et al., 1999). In seven
studies the number of patients with polycystic ovaries was
stated (Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale
et al., 1993, 1998; Farhi et al., 1993; White et al., 1996;
Strowitzki et al., 1998).
Details of baseline testosterone levels were provided in
nmol/l (Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale
et al., 1993, 1998; Fulghesu et al., 1997) or converted to SI
units when expressed as ng/ml (Farhi et al., 1993; Strowitzki
et al., 1998; Yarali et al., 1999; Vicino et al., 2000). Data
regarding androstenedione levels were provided in nmol/l
(Dale et al., 1993, 1998; Fulghesu et al., 1997; Vicino et al.,
2000) or converted to SI units (Vicino et al., 2000).
Details concerning baseline LH levels for patients or
subgroups of patients were provided in IU/l in eight studies
(Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale et al.,
1993, 1998; Farhi et al., 1993; Fulghesu et al., 1997; Strowitzki
et al., 1998; Vicino et al., 2000) or converted when expressed
as mIU/ml (Vicino et al., 2000). Baseline LH/FSH ratios were
provided by eight studies (Sagle et al., 1991; Farhi et al., 1993;
Balasch et al., 1996; Fulghesu et al., 1997; Dale et al., 1998;
Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000).
Dale et al. (1998) assessed insulin resistance and glucose
tolerance by means of a continuous infusion of glucose with
CIGMA (continuous infusion of glucose with model assess-
ment) model assessment test. Fulghesu et al. (1997) classi®ed
patients as hyperinsulinaemic or normoinsulinaemic based on
the insulinaemic response to glucose load (OGTT). Both
studies (Fulghesu et al., 1997; Dale et al., 1998) provided data
of fasting glucose (nmol/l) and insulin levels (mIU/l).
Conversion to IU units was performed where necessary.
Pooling of data
Data from studies reporting relationships between initial
screening characteristics and outcome parameters of ovulation
induction as measures of association (OR) were pooled if at
least two studies reported an association of similar screening
parameter and outcome characteristic. The measures of
association were pooled using the inverse of the variance as
weight. Heterogeneity was tested for using the Q statistic as
de®ned by DerSimonean and Laird, which has a c2 distribution
with df = (number of pooled studies ± 1) (DerSimonian and
Laird, 1986). Random effects estimates were calculated using
the likelihood method described by Hardy and Thompson
Table III. Possible clinical and endocrine features involved in the total amount of gonadotrophins administered (IU) during gonadotrophin induction of
ovulation in normogonadotrophic anovulatory infertility (see also Figure 1)
Study No. of (cycles) Mean IU (SD) Mean difference in IU (95% CI)
Obesitya Testosterone LH Insulin resistanceb
Balasch et al. (1996) 534 1185 (900) ± ± ± ±
Dale et al. (1993) 66 1702 (925) 759 (346±1172) ± ± 741 (290±1192)
Dale et al. (1998) 70 1611 (949) 449 (46±852) ± ± ±
Farhi et al. (1993) 195 1979 (1027) ± ± ± ±
Fulghesu et al. (1997) 52 1462 (638) 263 (-59±585) ± ± 113 (±241±466)
Hamilton-Fairley et al. (1992) 405 1360 (719) 1013 (848±1177) ± ± ±
McClure et al. (1992)c,d 181 1483 (640) 892 (706±1079) ± ± ±
McClure et al. (1993) ± ± ± ± ± ±
Sagle et al. (1991) 75 1269 (475) ± ± ± ±
Strowitzki et al. (1998) 116 1110 (567) 33 (±173±238) ± ± ±
Vicino et al. (2000) 107 1444 (578) 908 (801±1014) ± ± ±
White et al. (1996) 429 1140 (785) ± ± ± ±
Yarali et al. (1999) 96 1145 (762) ± ± ± ±
Pooled estimates 2326 1358 ± ± ± ±
WMD (95% CI) 771 (700±842) ± ± 351 (73±630)
Random effects model 629 (317±931) ± ± ±
Test for heterogeneity P < 0.001 ± ± ±
aObesity versus total amount of gonadotrophins administered expressed as: weighted mean difference (WMD) in IU: WMD based on obese versus non-obese
patients (applied threshold varied from study to study: range 25±30 kg/m2).
bInsulin resistance versus total amount of gonadotrophins administered expressed as: WMD in IU: WMD based on hyperinsulinaemic versus normoinsulinaemic
patients (applied de®nition varied between studies).
cTotal dose in IU deducted from ®gure: data not stated in results/table (McClure et al., 1992).
dOnly ovulatory cycles included for the present analysis (i.e. total amount of gonadotrophins administered) (McClure et al., 1992).
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(1998), when at least three studies were available. Association
measures were extracted from studies for the following
outcome parameters: total amount of FSH administered
(Table III), cancellation rate (Table IV), ovulation rate
(Table V), pregnancy rate (Table VI and Table VII) and
miscarriage rate (Table VIII).
Results of pooling
A total number of seven studies reported an association (all
positive) between obesity and total amount of gonadotrophins
administered (IU) (Figure 1) (Hamilton-Fairley et al., 1992;
McClure et al., 1992; Dale et al., 1993, 1998; Fulghesu et al.,
Table IV. Possible clinical and endocrine features involved in the observed cancellation rate during gonadotrophin induction of ovulation in
normogonadotrophic anovulatory infertility (see also Figure 2)
Study No. of (cycles) No. of cancelled (%) Obesitya Testosterone LH Insulin resistanceb
OR (95% CI) OR (95% CI) OR (95%CI) OR (95%CI)
Balasch et al. (1996) 534 93 (17) ± ± ± ±
Dale et al. (1993) 66 11 (17) 0.69 (0.18±2.61) ± ± 21.10 (2.51±176.62)
Dale et al. (1998) 70 11 (16) 0.82 (0.23±2.89) ± ± ±
Farhi et al. (1993) 195 ± ± ± ± ±
Fulghesu et al. (1997) 52 ± ± ± ± ±
Hamilton-Fairley et al. (1992) 405 ± ± ± ± ±
McClure et al. (1992) 224 14 (6) ± ± ± ±
McClure et al. (1993) ± ± ± ± ± ±
Sagle et al. (1991) 75 3 (4) ± ± ± ±
Strowitzki et al. (1998) 116 30 (26) 1.89 (0.81±4.41) ± ± ±
Vicino et al. (2000) 107 39 (36) 3.84 (1.68±8.80) ± ± ±
White et al. (1996) 429 76 (18) ± ± ± ±
Yarali et al. (1999) 96 11 (16) ± ± ± ±
Pooled estimates 2369 288 (17) ± ± ± ±
Fixed effects OR (95% CI) 1.86 (1.13±3.06) ± ± ±
Test for heterogeneity P = 0.2 ± ± ±
aOdds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range
25±30 kg/m2).
bOR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies).
Table V. Possible clinical and endocrine features involved in the observed ovulation rate during gonadotrophin induction of ovulation in normogonadotrophic
anovulatory infertility (see also Figure 3)
Study No. of No. of ovulatory Obesitya Testosterone LH Insulin resistanceb
cycles cycles (%) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Balasch et al. (1996) 534 419 (79) ± ± ± ±
Dale et al. (1993) 66 49 (74) ± ± ± ±
Dale et al. (1998) 70 ± ± ± ± ±
Farhi et al. (1993) 195 146 (75) ± ± ± ±
Fulghesu et al. (1997) 52 44 (85) ± ± ± 0.87 (0.18±4.09)
Hamilton±Fairley et al. (1992) 405 292 (72) 0.39 (0.24±0.63) ± ± ±
McClure et al. (1992) 224 181 (81) ± ± ± ±
McClure et al. (1993) ± ± ± ± ± ±
Sagle et al. (1991) 75 61 (81) ± ± 1.12 (1.02±1.24)c ±
Strowitzki et al. (1998) 116 86 (74) 0.53 (0.23±1.23) ± ± ±
Vicino et al. (2000) 107 68 (64) 0.26 (0.11±0.60) ± ± ±
White et al. (1996) 429 305 (71.1) ± 0.68 (0.44 ±1.05)d 1.02 (0.65±1.59)d ±
Yarali et al. (1999) 51 39 (76.5) 0.78 (0.36±1.71)e ± ± ±
Pooled estimates 2324 1690 (75) ± ± ± ±
Fixed effects OR (95% CI) 0.44 (0.31± 0.61) ± f ±
Test for heterogeneity P = 0.4 ± ± ±
aOdds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range 25±30 kg/
m2).
bOR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies).
cIndirect calculation of OR: based on continuous data (deducted from ®gure) (Sagle et al., 1991).
dOR calculated based on subdivision of testosterone and LH serum levels (respectively testosterone >2.6 nmol/l or <2.7 nmol/l and LH >11.0 IU/l or <11.1 IU/
l) (White et al., 1996).
eOnly ®rst cycle data included in the present analysis (Yarali et al., 1999).
fPooled OR not calculated because continuous (Sagle et al., 1991) and categorical (White et al., 1996) data were provided by either studies.
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Table VI. Possible clinical and endocrine features involved in the observed pregnancy rate per cycle during gonadotrophin induction of ovulation in
normogonadotrophic anovulatory infertility
Study No. of cycles No. of pregnancies (%) Obesitya Testosterone LH Insulin resistanceb
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Balasch et al. ( 1996) 534 93 (17) ± ± ± ±
Dale et al. (1993) 66 12 (18) 1.35 (0.38±4.72) ± ± 0.14 (0.03±0.69)
Dale et al. (1998) 70 16 (23) ± ± ± ±
Farhi et al. (1993) 195 35 (18) ± ± ± ±
Fulghesu et al. (1997) 52 11 (21) ± ± ± 0.48 (0.13±1.85)
Hamilton-Fairley et al. (1992) 405 45 (11) 1.7 (0.87±3.30) ± ± ±
McClure et al. (1992) 224 45 (20) ± ± ± ±
McClure et al. (1993) ± ± ± ± ± ±
Sagle et al. (1991) 75 10 (13) ± ± ± ±
Strowitzki et al. (1998) 116 21 (18) 0.60 (0.23±1.59) ± ± ±
Vicino et al. (2000) 107 8 (8) 0.45 (0.09±2.35)c ± ± ±
White et al. (1996) 429 49 (11) ± 0.93 (0.51±1.69)d 1.61 (0.88±2.94)d ±
Yarali et al. (1999) 96 21 (22) ± ± ± ±
Pooled estimates 2369 366 (15) ± ± ± ±
Fixed effects OR (95% CI) 1.13 (0.70±1.84) ± ± 0.29 (0.10±0.80)
Test for heterogeneity P = 0.4 ± ± ±
aOdds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range
25±30 kg/m2).
bOR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies).
cVicino et al. (2000) provides continuous data of BMI for pregnant versus non-pregnant women: assume BMI is normally distributed among pregnant versus
non-pregnant women: calculate the fraction obese versus non-obese (232 table constructed): indirect calculation of OR (based on number of cycles): 0.45.
dOR calculated based on subdivision of testosterone and LH serum levels (respectively testosterone >2.6 nmol/l or <2.7 nmol/l and LH >11.0 IU/l or <11.1
IU/l) (White et al., 1996).
Table VII. Possible clinical and endocrine features involved in the observed pregnancy rate per patient during gonadotrophin induction of ovulation in

















Balasch et al. (1996) 234 2.3 93 (40) ± ± 1.07 (1.06±1.16) ±
Dale et al. (1993) 50 1.3 12 (24) ± ± ± 0.10 (0.02±0.56)
Dale et al. (1998) 42 1.7 16 (38) ± ± ± ±
Farhi et al. (1993) 89 2.2 35 (39) 2.95 (1.09±7.96)c 0.90 (0.73±1.12) 1.00 (0.96±1.04) ±
Fulghesu et al. (1997) 34 1.5 11 (32) ± ± ± 0.44 (0.10±1.92)
Hamilton-Fairley et al. (1992) 100 4.1 45 (45) 2.25 (0.89±5.67) ± ± ±
McClure et al. (1992) 71 3.2 45 (63) ± ± ± ±
McClure et al. (1993) ± ± ± ± ± ± ±
Sagle et al. (1991) 30 2.5 10 (33) ± ± ± ±
Strowitzki et al. (1998) 68 1.7 21 (31) 0.59 (0.21±1.69) ± ± ±
Vicino et al. (2000) 21 5.1 8 (38) 0.39 (0.06±2.70) 0.95 (0.70±1.29) 0.73 (0.35±1.53) ±
White et al. (1996) 91 4.7 49 (54) 0.79 (0.35±1.80)c 1.0 (0.73±1.37) 1.01 (0.96±1.08) ±
Yarali et al. (1999) 51 1.9 21 (41) ± ± ± ±
Pooled estimates 881 2.7 366 ± ± ± ±
Fixed effects OR (95% CI) 1.22 (0.77±1.93)d 0.94 (0.80 ±1.09)e 1.04 (1.01 ±1.07)f 0.24 (0.08±0.71)
Test for heterogeneity P = 0.16 ± ± ±
aOdds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range 25±30 kg/m2).
bOR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies).
cFarhi et al. (1993) and White et al. (1996) both provide continuous data of BMI for pregnant versus non-pregnant women: assume BMI is normally distributed
among pregnant versus non-pregnant patients: calculate the fraction obese and non-obese patients (232 table constructed): indirect calculation of OR (based on
number of patients): 2.95 and 0.79 respectively.
dSecond best analysis performed (per patient), because not all studies provided data per cycle: analysis based on obese versus non-obese patients (applied
threshold varied from study to study: range 25±30 kg/m2): obesity versus pregnancy rate expressed as: OR.
eFor testosterone levels expressed as SI units (nmol/l) pooled analysis was performed (Farhi et al., 1993; White et al., 1996; Vicino et al., 2000).
fFor LH levels expressed as SI units (IU/l) pooled analysis was performed (Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Vicino et al., 2000).
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1997; Strowitzki et al., 1998; Vicino et al., 2000). The
weighted mean difference (WMD) (obese versus non-obese)
for total dose used was 771 (95% CI: 700±842) IU. Signi®cant
heterogeneity was detected between studies (P < 0.001). The
random effects estimate of the difference between obese and
non-obese patients was 629 (95% CI: 317±931) IU. Two
studies reporting on insulin resistance versus total amount of
FSH administered (Fulghesu et al., 1997; Dale et al., 1998)
Table VIII. Possible clinical and endocrine features involved in the observed miscarriage rate during gonadotrophin induction of ovulation in
normogonadotrophic anovulatory infertility (see also Figure 5)
Study No. of pregnancies Mean no. Obesitya Testosterone LH Insulin resistanceb
of miscarriages (%) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Balasch et al. (1996) 93 10 (11) ± ± ± ±
Dale et al. (1993) 12 4 (33) ± ± ± ‘
Dale et al. (1998) 16 7 (44) ± ± ± ±
Farhi et al. (1993) 35 13 (37) ± ± ± ±
Fulghesu et al. (1997) 11 2 (18) ± ± ± 1.25 (0.06±26.9)
Hamilton±Fairley et al. (1992) 45 17 (38) 4.13 (1.11±15.32) ± ± ±
McClure et al. (1992) 45 12 (27) ± ± ± ±
McClure et al. (1993) 50 14 (28) 1.44 (0.35±5.84)c ± 1.004 (0.93±1.09) ±
Sagle et al. (1991) 10 4 (40) ± ± ± ±
Strowitzki et al. (1998) 21 3 (14) 4.0 (0.30±53.47) ± ± ±
Vicino et al. (2000) ± ± ± ± ± ±
White et al. (1996) 49 13 (27)d 4.12 (1.08±15.71)c 0.86 (0.54±1.37) 1.03 (0.93±1.14) ±
Yarali et al. (1999) 21 4 (19) ± ± ± ±
Pooled estimates 408 288 (17) ± ± ± ±
Fixed effects OR (95% CI) 3.05 (1.45±6.44) ± 1.013 (0.95±1.08)e 1.8 (0.3±10.3)
Test for heterogeneity P = 0.17 ± ± ±
aOdds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range
25±30 kg/m2).
bOR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies).
cMcClure et al. (1993) and White et al. (1996) both provide continuous data of BMI for pregnant versus non-pregnant women: assume BMI is normally
distributed among pregnant versus non-pregnant patients: calculate the fraction obese and non-obese patients (232 table constructed): indirect calculation of
OR (based on number of patients): 1.44 and 4.12 respectively.
dMiscarriage: ectopic pregnancy included (White et al., 1996).
eFor LH levels expressed as SI units (IU/l) pooled analysis was performed (McClure et al., 1993; White et al., 1996).
Figure 1. Association measures between obesity and total amount of gonadotrophins administered (IU) for ovulation induction in normogonadotrophic
anovulatory infertility (median and 95% con®dence interval). The weighted mean difference (WMD) was generated using inverse variance weighting.
Heterogeneity was tested for and random effects estimates were calculated using the likelihood method as described by Hardy and Thompson (1998).
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produced a WMD (hyperinsulinaemic versus normoinsulinae-
mic) of 351 (95% CI: 73±630) IU.
Four studies reported an association between obesity and
cancellation rate (Dale et al., 1993, 1998; Strowitzki et al.,
1998; Vicino et al., 2000) (Figure 2). The pooled OR (obese
versus non-obese) was 1.86 (95% CI: 1.13±3.06). Despite
con¯icting directions of association, the test for heterogeneity
was not signi®cant (P = 0.2).
Four studies (Hamilton-Fairley et al., 1992; Strowitzki et al.,
1998; Yarali et al., 1999; Vicino et al., 2000) reported an
association between obesity and ovulation rate, with a pooled
OR (obese versus non-obese) of 0.44 (95% CI: 0.31±0.61)
(Figure 3). The test for heterogeneity was not signi®cant (P =
0.4). Two studies (Sagle et al., 1991; White et al., 1996)
reported an association between LH and ovulation rate. Pooling
of the results was not possible because one study reported LH
as a continuous variable (Sagle et al., 1991) and the other
provided data of LH in two categories (White et al., 1996).
Association measures for respectively testosterone (White
et al., 1996) and insulin resistance (Fulghesu et al., 1997) with
ovulation were calculated from the data provided.
Pregnancy was analysed per cycle and per patient. Four
studies reported an association (three positive and one nega-
tive) between obesity and pregnancy rate per cycle, pooled OR
(obese versus non-obese) 1.13 (95% CI: 0.70±1.84) (Hamilton-
Fairley et al., 1992; Dale et al., 1993; Strowitzki et al., 1998;
Vicino et al., 2000). The test for heterogeneity was not
signi®cant (P = 0.4). Five studies reported an association (two
positive and three negative) between obesity and pregnancy
rate per patient (Hamilton-Fairley et al., 1992; Farhi et al.,
1993; White et al., 1996; Strowitzki et al., 1998; Vicino et al.,
2000). The pooled OR (obese versus non-obese) was 1.22 (95%
CI: 0.77±1.93). The test for heterogeneity was not signi®cant
(P = 0.16). Three studies (Farhi et al., 1993; White et al., 1996;
Vicino et al., 2000) reported an association between testoster-
one and pregnancy rate per patient. The pooled OR (per nmol/l)
was 0.94 (95% CI: 0.80±1.09). Four studies (Farhi et al., 1993;
Balasch et al., 1996; White et al., 1996; Vicino et al., 2000)
reported an association between LH and pregnancy rate per
patient (Figure 4). The pooled OR (per IU/l) was 1.04 (95% CI:
1.01±1.07). The test for heterogeneity was not possible in the
latter two cases. Association measures between insulin resist-
ance and pregnancy rate per cycle as well as per patient
(Fulghesu et al., 1997; Dale et al., 1998) were calculated. Both
studies (Fulghesu et al., 1997; Dale et al., 1998) reported a
negative association between insulin resistance and pregnancy
rate, with pooled OR (hyperinsulinaemic versus normoinsuli-
naemic) of 0.29 (95% CI: 0.10±0.80) and 0.24 (95% CI: 0.08±
0.74).
Four studies reported an association between obesity and
miscarriage rate (Figure 5) (Hamilton-Fairley et al., 1992;
McClure et al., 1993; White et al., 1996; Strowitzki et al.,
1998). The pooled OR (obese versus non-obese) was 3.05 (95%
CI: 1.45±6.44). The test for heterogeneity was not signi®cant (P
= 0.17). Two studies (McClure et al., 1993; White et al., 1996)
reported an association between LH and miscarriage rate. The
pooled OR (per IUl/l) was 1.013 (95% CI: 0.95±1.08). Two
studies (Fulghesu et al., 1997; Dale et al., 1998) reported an
Figure 2. Four studies reported an association between obesity and cancellation rate. The pooled odds ratio and 95% con®dence interval (obese versus non-
obese) was calculated by inverse variance weighting.
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association between insulin resistance and miscarriage rate.
The pooled OR (hyperinsulinaemic versus normoinsulinaemic)
was 1.75 (95% CI: 0.30±10.3). An association of age (McClure
et al., 1993) versus testosterone (White et al., 1996) and
miscarriage rate was calculated from the data provided.
None of the studies provided a measure of association
between CRA/CCF or the presence of polycystic ovaries and
treatment outcome.
In summary, signi®cant associations were found for the total
amount of FSH administered, cancellation rate, ovulation rate
Figure 3. Four studies reported an association between obesity and ovulation rate, with a pooled odds ratio and 95% con®dence interval (obese versus non-
obese) generated calculated by inverse variance weighting. Note: the range of the x-axis is different from Figure 2.
Figure 4. Association measures between LH (per IU/l) and pregnancy rate per patient was provided by a total number of four studies. The pooled odds ratio
and 95% CI (obese versus non-obese) was calculated by inverse variance weighting.
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and miscarriage rates with BMI. Furthermore, signi®cant
associations were found for the total amount of FSH and
pregnancy rate with insulin resistance.
Discussion
This systematic review and meta-analysis demonstrates how few
studies have provided measures of association between screening
characteristics in women with normogonadotrophic anovulatory
infertility and gonadotrophin ovulation induction treatment out-
come. The studies included used various criteria for patient
inclusion and intervention and are prone to bias. The best available
evidence suggests that obesity and insulin resistance are both
associated with adverse treatment outcomes, including increased
FSH requirements, increased cancellation and miscarriage rates
and most importantly decreased ovulation and pregnancy rates.
Obesity frequently coincides with normogonadotrophic anovu-
lation and represents an important clinical feature associated with
PCOS (Laven et al., 2002). Differences in pharmacokinetic
characteristics of gonadotrophin preparations (Mannaerts et al.,
1993) as well as the amount of exogenous gonadotrophins required
to achieve follicular maturation (Hamilton-Fairley et al., 1992;
McClure et al., 1992; Dale et al., 1993; Vicino et al., 2000; Imani
et al., 2002b) related to body weight, have been reported. Obesity
is associated with reduced circulating levels of sex hormone-
binding globulin (SHBG), mildly elevated androgen levels
(Poretsky et al., 1999) and hyperinsuliaemia (Norman et al.,
2002). Insulin resistance [associated with PCOS as well (Dunaif,
1999)] is also related to the total amount of gonadotrophins
administered, as previously reported (Homburg et al., 1996).
So far, the impact of obesity on the cycle cancellation rates in
women with anovulatory infertility has not been convincingly
established. However, the impact of obesity on ovulation rates was
previously mentioned by several authors (Hamilton-Fairley et al.,
1992; Yarali et al., 1999; Vicino et al., 2000). The present meta-
analysis explicitly shows that obese women are less likely to
ovulate following gonadotrophin ovulation induction and there-
fore suggests that ovarian dysfunction in these women is more
severe. However, differences in absorption and distribution of
exogenous FSH may also be involved (Mannaerts et al., 1993).
Weight reduction may normalize insulin resistance and androgen
metabolism (Kiddy et al., 1992; Holte et al., 1995) and may
signi®cantly improve menstrual abnormalities, ovulation, and
fertility rates (Norman et al., 2002).
Obesity does not seem to be associated with decreased
pregnancy rates, as previously reported (Hamilton-Fairley et al.,
1992; Dale et al., 1993; White et al., 1996; Strowitzki et al., 1998;
Vicino et al., 2000). It should be noted that some of these
conclusions were drawn based on studies of a selected group of
non-obese women (i.e. BMI <27 kg/m2). The current analysis,
however, shows an increased incidence of spontaneous miscar-
riage with increasing BMI in women with PCOS. This ®nding has
been reported before (Hamilton-Fairley et al., 1992). The present
analysis, though, shows that all other studies are in line with this
observation. This result again stresses the importance of weight
reduction. Likewise, it has been described that the incidence of
spontaneous miscarriage increases with decreasing insulin sensi-
tivity (Dale et al., 1998). However, the small number of
miscarriages precludes de®nitive conclusions in this regard.
Along these lines, it has been suggested that insulin-sensitizing
agents also reduce miscarriage rates (Glueck et al., 2001).
Figure 5. Four studies reported an association between obesity and miscarriage rate. The pooled odds ratio and 95% CI (obese versus non-obese) was
calculated by inverse variance weighting. Note: the range of the x-axis is different from Figure 2.
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Hyperandrogenism is considered to be a key feature in PCOS
and constitutes a hallmark for the diagnosis (Dunaif et al., 1992).
Intraovarian inhibitors of FSH action (such as the IGF system)
(Schipper et al., 1997; van Dessel et al., 1999) might possibly
promote follicle maturation arrest and concomitantly ovarian
hyperandrogenism (Giudice, 1999). Hyperandrogenism has pro-
ven to be a powerful predictor for the response to ovulation
induction, emphasizing its signi®cance for ovarian dysfunction in
these women (Imani et al., 1998, 1999, 2000, 2002a,b; Mulders
et al., 2003). The impact of these biologically plausible factors
involved in ovarian dysfunction in normogonadotrophic anovula-
tion, such as serum androgens and free IGF-I, unfortunately could
not be scrutinized in the current analysis, because of lack of data.
Elevated LH levels are frequently encountered in PCOS, but this
is not a mandatory diagnostic of PCOS (Laven et al., 2002).
Although it was previously reported that elevated serum LH
concentrations were associated with increased miscarriage rates on
the basis of retrospective studies (Howles et al., 1986; Balen et al.,
1993; Watson et al., 1993), prospective data do not support the
concept that elevated LH is implicated in ovarian dysfunction and
ovulation induction outcome (Imani et al., 2002a). The present
analysis, however, shows a small but signi®cant association of
elevated serum LH with increased pregnancy rates.
Upon pelvic ultrasound, ovaries of women with normogonado-
trophic anovulation might be enlarged (Puzigaca et al., 1991;
Pache et al., 1992), contain an increased number of follicles
(Obhrai et al., 1990; Jonard et al., 2003), and exhibit an increased
density of ovarian stroma (Dewailly, 1997). It has been shown that
the value of these sonographic parameters as a screening test to
predict endocrine abnormalities characteristic of PCOS is limited
(van Santbrink et al., 1997). In addition, sonographic parameters
are predictive of patients remaining anovulatory following
clomiphene citrate (Imani et al., 1998). Others recently described
a correlation between initial ovarian volume or mean follicle
number and subsequent response applying gonadotrophin induc-
tion of ovulation (van der Meer et al., 1998; Lass et al., 2002;
Mulders et al., 2003). These ®ndings could not be recon®rmed in
the current analysis since none of the included studies reported
suf®cient data to perform the analysis.
The association of advanced age with poorer treatment outcome
following clomiphene citrate- or FSH-induced cycles, as previ-
ously reported (McClure et al., 1993; Imani et al., 2002a; Mulders
et al., 2003), could not be con®rmed by the present meta-analysis
because of lack of data.
In summary, the current results are perhaps somewhat disap-
pointing. However, this should not be too surprising as most
studies did not intend to predict treatment outcome by patient
characteristics. The possibility that some conclusions from this
analysis may be affected by the repetitive inclusion of data cannot
be completely discarded. However, we believe that such effects, if
they exist, are minor. In addition, pooling of the original data ®les
rather than the published data might also have resulted in slightly
different outcomes. Principally, the association between initial
clinical screening parameters (re¯ecting the extent of ovarian
dysfunction in normogonadotrophic anovulatory infertility) and
treatment outcome deserves further attention. In addition, more
individualized ovulation induction treatment algorithms may
subsequently be developed. For the future, there is a need to
standardize the de®nitions of ovulation induction treatment
outcome in women with normogonadotrophic anovulatory infer-
tility (including PCOS). Live-birth from a singleton pregnancy
following gonadotrophin induction of ovulation could then be
more effectively achieved by treatment strategies individually
tailored on the basis of initial screening characteristics.
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